Purpose To assess the effects of intravitreal bevacizumab (Avastin) injections in the treatment of choroideal neovascularization (CNV) associated with multifocal choroiditis (MC). Methods Prospective interventional case series. Patients with MC complicated by subfoveal CNV underwent a complete ophthalmologic examination, including ETDRS visual acuity, optical coherence tomography (OCT), fluorescein angiography, and indocyanine green angiography. The protocol required 3 monthly consecutive injections, followed by repeated injections as needed. The planned follow-up was 12 months. Results Ten patients were enrolled in the study and prospectively followed up. Mean visual acuity and mean foveal thickness (FT) at the baseline were 0.58±0.48 (logMAR±SD) and 290±92µm SD, respectively. At the 3-month examination, mean visual acuity improved to 0.42±0.48 and mean FT decreased to 298±172µm SD. At the 12-month examination, mean visual acuity was 0.40±0.49, and mean FT was 255±163µm. No side-effect or complication was registered. Conclusion Intravitreal bevacizumab is a safe and beneficial treatment for CNV associated with MC in a short-term follow-up. A longer follow-up and a larger sample of patients are required to validate the results.
Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization Related to Multifocal Choroiditis
Battaglia Parodi M;F. Bandello
2009-01-01
Abstract
Purpose To assess the effects of intravitreal bevacizumab (Avastin) injections in the treatment of choroideal neovascularization (CNV) associated with multifocal choroiditis (MC). Methods Prospective interventional case series. Patients with MC complicated by subfoveal CNV underwent a complete ophthalmologic examination, including ETDRS visual acuity, optical coherence tomography (OCT), fluorescein angiography, and indocyanine green angiography. The protocol required 3 monthly consecutive injections, followed by repeated injections as needed. The planned follow-up was 12 months. Results Ten patients were enrolled in the study and prospectively followed up. Mean visual acuity and mean foveal thickness (FT) at the baseline were 0.58±0.48 (logMAR±SD) and 290±92µm SD, respectively. At the 3-month examination, mean visual acuity improved to 0.42±0.48 and mean FT decreased to 298±172µm SD. At the 12-month examination, mean visual acuity was 0.40±0.49, and mean FT was 255±163µm. No side-effect or complication was registered. Conclusion Intravitreal bevacizumab is a safe and beneficial treatment for CNV associated with MC in a short-term follow-up. A longer follow-up and a larger sample of patients are required to validate the results.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
